Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Systemic immune-inflammation index (SII), based on peripheral lymphocyte, neutrophil, and platelet counts, was recently investigated as a prognostic marker in several tumors. However, SII has not been reported in esophageal squamous cell carcinoma (ESCC). We evaluated the prognostic value of the SII in 916 patients with ESCC who underwent radical surgery. Univariate and multivariate analyses were calculated by the Cox proportional hazards regression model. The time-dependent receiver operating characteristics (ROC) curve was used to compare the discrimination ability for OS. PSM (propensity score matching) was carried out to imbalance the baseline characteristics. Our results showed that SII, PLR, NLR and MLR were all associated with OS in ESCC patients in the Kaplan-Meier survival analysis. However, only SII was an independent risk factor for OS (HR = 1.24, 95% CI 1.01–1.53, P = 0.042) among these systemic inflammation scores. The AUC for SII was bigger than PLR, NLR and MLR. In the PSM analysis, SII still remained an independent predictor for OS (HR = 1.30, CI 1.05–1.60, P = 0.018). SII is a novel, simple and inexpensive prognostic predictor for patients with ESCC undergoing radical esophagectomy. The prognostic value of SII is superior to PLR, NLR and MLR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Hu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493
Pennathur, A., Gibson, M. K., Jobe, B. A., & Luketich, J. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60643-6 · Cited by 2,390
Cancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Cited by
Items 201–234 of 234
Narayanaswamy, S., Postoev, A., ., Z., Sharma, A., Gunaratne, H., Chaudhary, S., Wei, C. R., & Ali, N. (2026) · Cureus · doi:10.7759/cureus.107928 · Cited by 1
“Previous research has demonstrated its prognostic relevance in malignancies [24,25], and more recent investigations have extended its application to cardiovascular diseases, chronic obstructive pulmonary disease, coronavirus infection, and other inflammatory conditions [26,27].”
Mora, A., Nakajima, Y., Okada, T., Hoshino, A., Tokairin, Y., Kawada, K., & Kawano, T. (2020) · International Surgery · doi:10.9738/intsurg-d-18-00012.1 · Cited by 1
Demirtaş, T., Tombul, Ş. T., Sönmez, G., & Demirtaş, A. (2021) · Medical Bulletin of Haseki · doi:10.4274/haseki.galenos.2021.7396 · Cited by 1
Sivrice, M. E., Kumbul, Y. Ç., Yasan, H., & Tüz, M. (2021) · kulak burun boğaz ve baş boyun cerrahisi dergisi · doi:10.24179/kbbbbc.2021-82505 · Cited by 1
Raczyński, I., Siedlaczek, A., Streb, J., Zając, P., Czartoryska-Arłukowicz, B., Chruściana-Bołtuć, A., Talerczyk, M., Wierzbicka, K., Radecka, W., Jurczyk, M., et al. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.98125 · Cited by 1
Schoppmann, S. F., & Jomrich, G. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003681
Mirili, C., Paydaş, S., Yılmaz, A., Oğul, A., Büyükşimşek, M., Yetişir, A. E., & Tohumcuoğlu, M. (2019) · Acta Oncologica Turcica · doi:10.5505/aot.2019.08760
“SII is an promising index in cancers such as hepatocellular cancer, pancreas, small and non-small cell lung cancer, gastric and esophagial cancers [13-16].”
BackgroundTHE INFLAMMATORY STATUS AND LYMPH NODE METASTASES IN NON-SMALL CELL LUNG CANCER
Сергеевич, П. Д., Savelieva, O. E., Zavyalova, M. V., Родионов, Е. О., Таширева, Л. А., Тузиков, С. А., Pankova, O. V., & Михайлович, П. В. (2020) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2020-19-3-54-63
“The systemic immuno-inflammatory index (SII) is the most informative among these indices [10, 11].”
BackgroundWu, W., Wang, C., Jiang, J., Zhang, Z., Feng, C., Zhao, Y. F., & Lin, F. (2022) · Research Square · doi:10.21203/rs.3.rs-2093580/v1
Self-citationThe Prognostic Importance of the Systemic Inflammatory Index in Pathologies of the Larynx
Topuz, M. F., Sivas, Z. Z., Türe, N., & Oğhan, F. (2023) · kulak burun boğaz ve baş boyun cerrahisi dergisi · doi:10.24179/kbbbbc.2022-94083
Demirdöğen, Ş. O., Cinislioğlu, A. E., Aksakallı, T., Altay, M. S., Utlu, A., Karabulut, İ., & Özbey, İ. (2023) · Androloji Bülteni · doi:10.24898/tandro.2023.34603
Xiang, X., Tang, Y., Li, N., Liu, W., Chen, S., Zhao, Y., Shi, J., Zeng, Q., Ma, H., Wang, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3336246/v1
Geçkalan, D., & Gülcan, A. (2024) · Journal of Pediatric Infectious Diseases · doi:10.1055/s-0044-1788655
Yıldız, S., Emir, B. S., Kılıçaslan, A. K., Kurt, O., Uğur, K., Sehlikoğlu, Ş., & Atmaca, M. (2024) · Journal of Forensic Psychiatry and Psychology · doi:10.1080/14789949.2024.2429663 · Cited by 1
“The systemic immune-inflammatory index (SII), a newer marker, has been suggested to reflect inflammation and immune response more accurately than NLR and MLR and has been used to predict prognosis (Geng et al., 2016), particularly in cardiovascular diseases (Ye et al., 2022).”
Kara, A., & Elden, H. (2024) · Online Türk Sağlık Bilimleri Dergisi · doi:10.26453/otjhs.1576219
New Inflammatory Indexes in Diabetic Neuropathy
Tuncer, T., & Karakeci, E. S. (2025) · Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi · doi:10.31609/jpmrs.2024-105182
Wang, J., Hou, L., Li, C., Liu, Y., Xu, Y. H., He, Y., Yang, L., Wang, L., Liu, Q., Cheng, J., et al. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08150-6
“SII and SIRI, which integrate multiple immune cell types, are considered more comprehensive indices than single ratios such as NLR or PLR [54].”
The Role of Systemic Immune-Inflammation Index in Severe Bicuspid Aortic Stenosis
Süygün, H. (2025) · The European Research Journal · doi:10.18621/eurj.1759091
Chen, W., Ju, X., & Chao, B. (2025) · Discover Oncology · doi:10.1007/s12672-025-04186-4
“…lymphocytes, monocytes, platelets, C-reactive protein (CRP), and their derived ratios—such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mono-cyte-to-lymphocyte ratio (MLR)—have been validated as being linked to the prognosis of diverse malignant neoplasms [5–7].”
Zeng, P., Jiang, C. S., Liu, A., Yang, X., Lin, F., & Cheng, L. (2024) · Figshare · doi:10.6084/m9.figshare.25001694
ZUBRICKIY, V., Mikhaylichenko, V. Y., KOROLEVA, E., Kaibov, I., & Chernavskiy, S. (2025) · Медицинский вестник МВД · doi:10.52341/20738080_2025_134_1_13 · Cited by 1
Sarışen, Ş., Bozkuş, R., & Cesur, E. M. (2026) · Family practice and palliative care · doi:10.22391/fppc.1653691
Vajda, G., Lakatos, K. F., Lőczi, L., Vida, B., Ács, N., Sebők, B., Szabó, V., Tabányi, Á., Lintner, B., Tóth, R., et al. (2026) · Cancers · doi:10.3390/cancers18071114
“…between SIRI and both progression-free and overall survival in nasopharyngeal carcinoma [25] and soft tissue sarcoma [23], whereas the prognostic relevance of SII has been confirmed in colorectal cancer [26], esophageal squamous cell carcinoma [27], and oral squamous cell carcinoma [28].”
Sakamoto, T., Uehira, K., Yoshida, J., Kishino, M., Morimoto, M., Murakami, Y., Miyatani, K., Shishido, Y., Kihara, K., Matsunaga, T., et al. (2026) · World Journal of Surgical Oncology · doi:10.1186/s12957-026-04370-y
Determining acceptable duration for chemoradiation of esophageal squamous cell carcinoma
Kam, K.-H., Lee, C., Chang, J.-M., Yang, H., Chang, C.-C., Tsang, Y., Wang, Y., Wang, W.-Y., Kuo, C., Lee, M., et al. (2026) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001383
Zhang, C., Ni, Y., & Han, D. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1696646
“…highlighted its prognostic relevance in oncology, where higher SII values have been linked with tumor progression, limited therapeutic response, and poorer survival outcomes across several cancer types, including lung (42, 43), gastrointestinal (44, 45), and hepatocellular malignancies (14, 46).”
Li, J., Fang, L., & Tan, C. (2026) · BMC Pediatrics · doi:10.1186/s12887-026-07061-5
“SII has demonstrated significant prognostic value in several malignancies, including hepatocellular carcinoma [10], esophageal cancer [11], colorectal cancer [12], and cervical cancer [13].”
SOAT1 expression associates with prognosis, immune environment and biochemical indicators in glioma
Hu, W., Liang, W., Guo, X., Wang, F., Jing, Z., Lu, B., Li, H., Zhou, S., Huo, A., Zhao, C., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05328-y
“The Systemic Immune-Inflammation Index (SII), which is a composite score based on peripheral blood platelet, neutrophil, and lymphocyte counts, has been validated by multiple studies as an important prognostic and immune-inflamma-tion marker for cancer patients [20–22].”
Yu, J., Zhou, J., Sun, M., Wan, J., Chen, X. Q., Dou, X., & Ye, F. (2026) · Medicine · doi:10.1097/md.0000000000049127 · Cited by 1
“Initially developed to assess the prognosis of hepatocellular carcinoma, [13] SII has since been used to evaluate the prognostic value of various malignancies, [31,32] cardiovascular events, [33,34] infectious diseases, [35] and other conditions, demonstrating strong predictive capabilities.”
Özyılmaz, C., & Poyrazoğlu, İ. S. (2026) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2026.104883
Chou, Y., Huang, C.-H., Chen, P., & You, S.-J. (2026) · Cancer Management and Research · doi:10.2147/cmar.s599334
“In our cohort, SII demonstrated parallel elevation patterns, consistent with findings in esophageal 28 and lung cancers, 29 including the PROCLAIM trial, 30 which indicates that SII elevation represents a general systemic reaction to multimodality treatment.”
Zou, T., Wang, X., Wu, H., Li, Z., Chai, L., & Hao, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1833639
Ou, Y., Liu, Q., Yang, D., Chen, L., & Yu, J. (2026) · Cancer Medicine · doi:10.1002/cam4.72431
Metadata
- Authors
- Geng, Y., Shao, Y., Zhu, D., Zheng, X., Zhou, Q., Zhou, W., Ni, X., Wu, C., & Jiang, J.
- Affiliations
- Soochow University (CN)
- Corresponding author
- Wu, Changping
- Jiang, Jingting
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-12-21
- Volume
- 6
- Issue
- 1
- Pages
- 39482-39482
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5175190
- OpenAlex
- W2563208071
- Cited by
- 233
- References
- 29
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 36 · 2023: 33 · 2022: 24 · 2021: 41 · 2020: 23 · 2019: 23 · 2018: 16 · 2017: 7
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (31570877, 81301960)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- systemic immune-inflammation index, esophageal squamous cell carcinoma, prognostic factors, overall survival, radical esophagectomy, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic inflammation, lymphocyte count, platelet count, neutrophil count
- MeSH terms
- Esophageal Squamous Cell Carcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Esophageal Neoplasms, Female, Humans, Immunity, Inflammation, Male, Middle Aged, Prognosis, Regression Analysis, Retrospective Studies, Risk Factors, ROC Curve, Multivariate Analysis, Proportional Hazards Models, Esophagectomy, Kaplan-Meier Estimate, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.